Drug Profile
Glucagon intranasal - Amphastar Pharmaceuticals
Alternative Names: AMG504-1; Baqsimi; Dry-mist intranasal glucagon - Locemia Solutions; Glucagon - Locemia Solutions; Glucagon intranasal - Eli Lilly and Company/Locemia Solutions; LY 900018Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AMG Medical
- Developer Eli Lilly and Company; Locemia Solutions
- Class Antihypoglycaemics; Pancreatic hormones
- Mechanism of Action Glucagon receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypoglycaemia
- Phase I Type 1 diabetes mellitus
- No development reported Common cold
Most Recent Events
- 03 Nov 2023 Eli Lilly and Company completes a phase I trial for Type 1 diabetes mellitus (In children, In infants) in USA (Intranasal, Powder) (NCT04992312)
- 24 Apr 2023 Amphastar Pharmaceuticals purchases worldwide rights to Baqsimi® from Eli Lilly and Company
- 31 Dec 2022 Eli Lilly has data protection for glucagon intranasal in Japan until 2026